Characterization of circulating tumor cells in newly diagnosed breast cancer

Xu,Lu; Jia,Songlin; Li,Hengyu; Yu,Yue; Liu,Guoping; Wu,Yanmei; Liu,Xishui; Liu,Chaoqian; Zhou,Yue; Zhang,Zhenzhen; Sheng,Yuan

doi:10.3892/ol.2017.7540

Characterization of circulating tumor cells in newly diagnosed breast cancer

Authors:
- Lu Xu
- Songlin Jia
- Hengyu Li
- Yue Yu
- Guoping Liu
- Yanmei Wu
- Xishui Liu
- Chaoqian Liu
- Yue Zhou
- Zhenzhen Zhang
- Yuan Sheng
View Affiliations

Affiliations: Department of Breast Surgery, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China, Biotecan Medical Diagnostics Co., Ltd., Zhangjiang Center for Translational Medicine, Shanghai 201204, P.R. China
Published online on: December 6, 2017 https://doi.org/10.3892/ol.2017.7540
Pages: 2522-2528

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of circulating tumor cells (CTCs) by surface marker expression and ploidy analysis [immunostaining‑fluorescence in situ hybridization (iFISH)] has been shown to be a highly sensitive method in the identification of certain solid cancers. In the present study, iFISH analysis was performed to identify CTCs in 184 patients with newly diagnosed non‑metastatic breast cancer, and the distribution of CTC subtypes was characterized based on cytokeratin (CK) expression and ploidy status. It was revealed that CTCs of non‑metastatic, aneuploid breast cancers, independent of CK expression profile, can be detected with high sensitivity (90.76%) by the iFISH system. Higher CTC counts and sensitivity were observed in patients with increased tumor size burden and unfavorable hormone receptor status. Investigation of CTC subtypes based on ploidy analysis indicated that triploid CTCs constituted the majority of CTCs evaluated. While CK‑positive CTCs were detected in a small cohort of patients, an overall low rate of CK expression was observed in the 18 patient samples evaluated. Of note, CK expression was rare in CTCs detected in patients with Herceptin 2 (Her2)‑positive or triple‑negative [estrogen receptor (ER)‑, progesterone receptor (PR)‑ and Her2‑negative], indicating that lack of ER and PR may result in promotion of epithelial‑mesenchymal transition and enhancement of tumor aggression.

View Figures

View References

1	McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
2	Xue P, Wu Y, Guo J and Kang Y: Highly efficient capture and harvest of circulating tumor cells on a microfluidic chip integrated with herringbone and micropost arrays. Biomed Microdevices. 17:392015. View Article : Google Scholar : PubMed/NCBI
3	Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, Bischoff FZ and Pircher TJ: Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol. 2011:2523612011. View Article : Google Scholar : PubMed/NCBI
4	Murray NP, Miranda R, Ruiz A and Droguett E: Diagnostic yield of primary circulating tumor cells in women suspected of breast cancer: The BEST (Breast Early Screening Test) study. Asian Pac J Cancer Prev. 16:1929–1934. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ge F, Zhang H, Wang DD, Li L and Lin PP: Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells. Oncotarget. 6:27049–27064. 2015. View Article : Google Scholar : PubMed/NCBI
6	Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American Society of Clinical Oncology, : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
7	Chen M, Palleschi S, Khoynezhad A, Gecelter G, Marini CP and Simms HH: Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: A multivariate analysis. Arch Surg. 137:606–610. 2002. View Article : Google Scholar : PubMed/NCBI
8	Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, et al: Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 17:22015. View Article : Google Scholar : PubMed/NCBI
9	Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF and Hunt KK: Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 196:81–87. 2008. View Article : Google Scholar : PubMed/NCBI
10	Alix-Panabières C and Pantel K: Circulating tumor cells: Liquid biopsy of cancer. Clin Chem. 59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
11	Sheng Y, Wang T, Li H, Zhang Z, Chen J, He C, Li Y, Lv Y, Zhang J, Xu C, et al: Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells. Oncotarget. 8:8801–8806. 2017.PubMed/NCBI
12	Hillig T, Horn P, Nygaard AB, Haugaard AS, Nejlund S, Brandslund I and Sölétormos G: In vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods. Tumour Biol. 36:4597–4601. 2015. View Article : Google Scholar : PubMed/NCBI
13	Min H, Jo SM and Kim HS: Efficient capture and simple quantification of circulating tumor cells using quantum dots and magnetic beads. Small. 11:2536–2542. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM and Lin P: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol. 4:30–36. 2009. View Article : Google Scholar : PubMed/NCBI
15	Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP and Shen L: Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 5:6594–6602. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Wang F, Ning N, Chen Q, Yang Z, Guo Y, Xu D, Zhang D, Zhan T and Cui W: Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. Int J Cancer. 136:1228–1233. 2015. View Article : Google Scholar : PubMed/NCBI
17	Cao Y, Paner GP and Rajan PB: Sentinel node status and tumor characteristics: A study of 234 invasive breast carcinomas. Arch Pathol Lab Med. 129:82–84. 2005.PubMed/NCBI
18	Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 10:599–605. 1992. View Article : Google Scholar : PubMed/NCBI
19	Sjögren S, Inganäs M, Lindgren A, Holmberg L and Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 16:462–469. 1998. View Article : Google Scholar : PubMed/NCBI
20	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
21	Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010. View Article : Google Scholar : PubMed/NCBI
22	Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 339:580–584. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cui X, Schiff R, Arpino G, Osborne CK and Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 23:7721–7735. 2005. View Article : Google Scholar : PubMed/NCBI
24	Thomas C and Gustafsson JÅ: The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 11:597–608. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B and Barsky SH: ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene. 29:1451–1462. 2010. View Article : Google Scholar : PubMed/NCBI